RCT with 217 patients treated with metformin and 206 controls, showing no significant difference with treatment. Limited information is provided in the preprint. Time since symptom onset is not specified. The trial may share some similar issues with the companion ivermectin trial .
Reis et al., 8/31/2021, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, 13 authors.
extended ER observation or hospitalization, 15.0% higher, RR 1.15, p = 0.56, treatment 32 of 217 (14.7%), control 27 of 206 (13.1%), ITT.
extended ER observation or hospitalization, 18.0% higher, RR 1.18, p = 0.50, treatment 217, control 206, per protocol.
risk of no virological cure, 3.8% lower, RR 0.96, p = 0.57, treatment 217, control 206, adjusted per study.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.